The Genome Editing Technologies Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to understand the industry and its underlying dynamics better. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
CRISPR has the potential to treat a wide range of infectious diseases, including viruses, bacteria, and fungi. CRISPR has a wide range of applications in the research of viral diseases and the creation of new therapies, and the discovery of RNA-targeting Cas nucleases has opened up new avenues for targeting RNA viruses, including SARS-CoV-2 vaccines.
The rise in chronic illnesses and infectious diseases is a primary driver of the genome editing technologies market
Cancer is one of the world's leading health problems, affecting millions of people of all ages and genders and having a significant influence on the quality of life. The cancer incidence rate was 20 million new in 2020 and is expected to reach 30 million new cases per year by 2040. Genome editing technologies provide new opportunities in fundamental cancer research and diagnostics, with advantages such as simple design, rapid operation, low cost, and robust scaling. CRISPR/Cas is a rapidly evolving editing technique that is been applied to almost all genomic targets. Several genome editing techniques, including zinc finger endonuclease (ZFN), transcription activator-like effector nuclease (TALEN), and the clustered regularly interspaced short palindromic repeats/CRISPR associated nuclease (CRISPR/Cas) system, have been developed to provide efficient gene editing for the treatment of cancers, infectious diseases, and genetic disorders. Furthermore, CRISPR gene editing is becoming an increasingly significant technique in the field of infectious disease research.CRISPR has the potential to treat a wide range of infectious diseases, including viruses, bacteria, and fungi. CRISPR has a wide range of applications in the research of viral diseases and the creation of new therapies, and the discovery of RNA-targeting Cas nucleases has opened up new avenues for targeting RNA viruses, including SARS-CoV-2 vaccines.
Personalization of gene therapy faces a significant barrier in genome editing technologies
Personalization is the most significant barrier to autologous therapies since it introduces unpredictability into the process, both qualitatively and quantitatively (e.g., the number of cells harvested from each patient). It complicates scaling the procedure and necessitates the development of flexible cell culture platforms to accommodate the variety in the kind and number of cells taken from patients. It implies that several platforms must be run in parallel using a scale-out method rather than a scale-up approach. Some contract development and manufacturing organizations (CDMOs) have already penetrated this market to serve this need.What Questions Should You Ask before Buying a Market Research Report?
- How is the Genome Editing Technologies market evolving?
- What is driving and restraining the Genome Editing Technologies market?
- How will each Genome Editing Technologies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
- How will the market shares for each Genome Editing Technologies submarket develop from 2022 to 2032?
- What will be the main driver for the overall market from 2022 to 2032?
- Will leading Genome Editing Technologies markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
- Who are the leading players and what are their prospects over the forecast period?
- What are the Genome Editing Technologies projects for these leading companies?
- How will the industry evolve during the period between 2020 and 2032? What are the implications of Genome Editing Technologies projects taking place now and over the next 10 years?
- Is there a greater need for product commercialization to further scale the Genome Editing Technologies market?
- Where is the Genome Editing Technologies market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Genome Editing Technologies market today, and over the next 10 years:
- Our 416-page report provides 154 tables and 279 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2032 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2032, the new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Genome Editing Technologies prices and recent developments.
Segments Covered in the Report
Type
- CRISPR
- TALEN
- ZFN
- Antisense
- Others
Application
- Cell Line Engineering
- Genetic Engineering
- Diagnostic applications
- Drug discovery & development
- Others
End-user
- Biotechnology companies
- Pharmaceutical companies
- Academic & Government Research Institutes
- Others
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- Spain
- United Kingdom
- France
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- UAE
- Rest of Latin America
Leading companies and the potential for market growth
- Agilent Technologies Inc.
- CRISPR Therapeutics AG
- Editas Medicine
- GenScript
- Lonza
- Merck KGaA
- Precision Biosciences
- Sangamo Therapeutics Inc.
- Tecan Life Sciences
- Thermo Fisher Scientific Inc.
How will the Genome Editing Technologies Market, 2022 to 2032 report help you?
In summary, this 410+ page report provides you with the following knowledge:- Revenue forecasts to 2032 for Genome Editing Technologies Market, 2022 to 2032 Market, with forecasts market by techniques and company size, each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2032 for four regional and 17 key national markets - See forecasts for the Genome Editing Technologies Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 12 of the major companies involved in the Genome Editing Technologies Market, 2022 to 2032.
Information found nowhere else
With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. The study is for everybody needing commercial analyses for the Genome Editing Technologies Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.Table of Contents
1 Report Overview
3 Premium Insights
4 Market Overview
5 Global Genome Editing Technologies Market Analysis by Type
6 Global Genome editing technologies Market Analysis by Application
7 Global Genome editing technologies Market Analysis by End-user
8 North America Genome editing technologies Market Analysis
9 Europe Genome editing technologies Market Analysis
10 Asia Pacific Genome editing technologies Market Analysis
11 Latin America Genome editing technologies Market Analysis
12 Middle East & Africa Genome editing technologies Market Analysis
13 Competitive Landscape
14 Conclusion and Recommendations
List of Tables
Companies Mentioned
- Agilent Technologies Inc.
- CRISPR Therapeutics AG
- Editas Medicine
- GenScript
- Lonza
- Merck KGaA
- Precision Biosciences
- Sangamo Therapeutics Inc.
- Tecan Life Sciences
- Thermo Fisher Scientific Inc.
- Beam Therapeutics
- Cardea Bio
- Caribou Biosciences
- CASPR Biotech
- CRISPR Therapeutics
- Editas Medicine
- eGenesis
- Emendo Biotherapeutics
- Genedit
- Graphite Bio
- Hera Biolabs
- Hudson River Biotechnology
- Inari Agriculture
- Inscripta Therapeutics
- Intellia Therapeutics
- KSQ Therapeutics
- Ligandal
- Locus Biosciences
- Mammoth Biosciences
- Ntrans
- Pairwise Plants
- Plantedit
- Poseida Therapeutics
- Refuge Biotechnologies
- Scribe Therapeutics
- Sherlock Biosciences
- SNIPR Biome
- Spotlight Therapeutics
- Synthetic Genomics
- Verve Therapeutics
- Academy of Sciences of Hong Kong
- Alimentos y Tecnologa Médica (ANMAT)
- American Society of Human Genetics (ASHG)
- Brazilian Health Regulatory Agency (Anvisa)
- Brazilian Research Institute for Neuroscience and Neuro-technology
- Canadian Food Inspection Agency
- Centre for Commercialization of Regenerative Medicine (CCRM)
- Centre for Computational Science and Engineering
- Chinese Academy of Sciences
- Food and Drug Administration
- La Administración Nacional de Medicamentos
- Ministry of Health
- Ministry of Science and Technology and the National Natural Science Foundation
- National Institutes of Health (NIH)
- Qatar Precision Medicine Institute (QPMI)
- the Instituto Nacional Central nico Coordinador de Ablación e Implante (INCUCAI)
- The Sao Paulo Scientific Foundation
- US National Academy of Sciences and Medicine